The sample size will be 25 patients randomized to each study arm. There will be a total of 5 arms (a total of 125 patients), with the study being divided based on patient proximity to the Johns Hopkins Hospital. Local patients (defined as those patients who are able to be physically present for all of the study sessions as well as follow-up appointments) will be randomized to 3 arms: control, TRIMM and intensive intervention. Distant patients (defined as patients who are not able to be present for all study sessions as well as follow-up appointments) will be randomized to 2 arms: control and TRIMM. Study procedures will involve screening and informed consent after initial consultation, baseline evaluation including medical clearance and completion of validated questionnaires. Randomization will be achieved by a computerized random number generator, with patients stratified based on age. Assessment tools will consist of the IIEF questionnaire, the Quality of Erection Questionnaire (QEQ) and health related quality of life instruments: RAND 12-item Health Survey (SF-12) and the Expanded Prostate Cancer index Composite Short Form (EPIC-26-sexual and urinary domains). Standard practice associated with surgery, blood transfusion and postoperative laboratory testing will be performed. Patients will be prescribed a phosphodiesterase type 5 inhibitor (sildenafil, tadalafil or vardenafil) at 1 month following surgery to be used as conventional "on-demand" therapy. Adverse event monitoring will be performed.